C. Dinney

发表

Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer

L. Kiemeney, U. Thorsteinsdóttir, K. Stefánsson, 2009, Nature Genetics.

Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8.

C. Dinney, D. McConkey, M. Bar‐eli, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

The potential role of gene therapy in the treatment of bladder cancer.

C. Dinney, L. Chung, J. Hsieh, 2000, The Urologic clinics of North America.

Intravesical Gene Therapy.

C. Dinney, V. Narayan, 2020, The Urologic clinics of North America.

Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer

J. Weinstein, K. Baggerly, H. Grossman, 2018, bioRxiv.

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer

Mauro A. A. Castro, J. Weinstein, K. Hoadley, 2019, European urology.

Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer

J. Weinstein, K. Baggerly, H. Grossman, 2018, bioRxiv.

Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior

K. Baggerly, Y. Lotan, B. Czerniak, 2017, Scientific Reports.

Dose dense MVAC prior to radical cystectomy: a real-world experience

C. Dinney, P. Spiess, S. Daneshmand, 2017, World Journal of Urology.

Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases

B. Czerniak, C. Dinney, Charles C. Guo, 2017, American journal of clinical pathology.

Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.

J. Weinstein, K. Baggerly, B. Czerniak, 2016, European urology.

Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer

Xiaoping Su, Woonyoung Choi, David J. McConkey, 2014, Nature Reviews Urology.

New insights into subtypes of invasive bladder cancer: considerations of the clinician.

C. Dinney, D. McConkey, W. Choi, 2014, European urology.

Efficient therapeutic gene delivery after systemic administration of a novel polyethylenimine/DNA vector in an orthotopic bladder cancer model.

C. Dinney, W. Benedict, R. Cristiano, 2003, Cancer research.

Modulation of DNA damage/DNA repair capacity by XPC polymorphisms.

J. Gu, Hushan Yang, Xifeng Wu, 2008, DNA repair.

Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.

C. Dinney, M. Pino, D. McConkey, 2007, Cancer research.

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.

K. Baggerly, B. Czerniak, E. Plimack, 2014, Cancer cell.

Upper tract urothelial carcinoma: impact of time to surgery.

V. Margulis, C. Wood, C. Dinney, 2012, Urologic oncology.

Expression of interleukin‐8 gene in radical prostatectomy specimens is associated with advanced pathologic stage

C. Bucana, D. Johnston, C. Dinney, 2005, The Prostate.

Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer

Jian Gu, Paolo Vineis, Simonetta Guarrera, 2009, Nature Genetics.

Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma.

A. El‐Naggar, C. Dinney, I. Fidler, 2001, The American journal of pathology.

Gene therapy for superficial bladder cancer

C. Dinney, W. Benedict, C. Rosser, 2001, Expert review of anticancer therapy.

Concepts for banking tissue in urologic oncology--the International Bladder Cancer Bank.

Susan Groshen, Núria Malats, Richard Sylvester, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer

J. Weinstein, D. Cogdell, B. Czerniak, 2020, iScience.

Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design

C. Dinney, A. Kamat, V. Narayan, 2021, The Journal of urology.

Sentinel lymph node dissection for penile carcinoma: the M. D. Anderson Cancer Center experience.

C. Dinney, A. V. von Eschenbach, C. Pettaway, 1995, The Journal of urology.

Therapy of spontaneous lung metastasis of murine renal adenocarcinoma by systemic administration of liposomes containing the macrophage activator CGP 31362.

C. Bucana, C. Dinney, I. Fidler, 1991, Cancer research.

Re: Impact of Risk Factors on the Performance of the Nuclear Matrix Protein 22 Point-of-Care Test for Bladder Cancer Detection

C. Dinney, R. Svatek, 2009 .

A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci

William Wheeler, Tony Fletcher, Paolo Vineis, 2010, Nature Genetics.

p53 and RB expression predict progression in T1 bladder cancer.

H. Grossman, C. Dinney, W. Benedict, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Accuracy of computed tomography for identifying locally advanced disease in patients with muscle-invasive bladder cancer

C. Ng, C. Dinney, A. Kamat, 2013 .

Clinical applications for targeted therapy in bladder cancer.

C. Dinney, W. Kassouf, L. Adam, 2005, The Urologic clinics of North America.

Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.

C. Dinney, L. Pagliaro, J. Slaton, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer

Sam S. Chang, J. Witjes, C. Dinney, 2018, World Journal of Urology.

Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis.

J. Weinstein, K. Baggerly, S. Scherer, 2019, Cell reports.

Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes.

C. Dinney, A. Kamat, V. Narayan, 2020, Urologic oncology.

Oncologic Equivalence between Laparoscopic/Robotic and Open Radical Cystectomy.

C. Dinney, N. Navai, 2016, The Journal of urology.

Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection.

C. Dinney, John W. Davis, M. Munsell, 2011, The Journal of urology.

Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB.

C. Dinney, D. McConkey, B. Mian, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33.

William Wheeler, Hideo Tanaka, Jianxin Shi, 2014, Human molecular genetics.

Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa.

Wolfgang Jäger, Yoshiyuki Matsui, Robert H. Bell, 2013, The Journal of urology.

Intravesical Ad-IFNα Causes Marked Regression of Human Bladder Cancer Growing Orthotopically in Nude Mice and Overcomes Resistance to IFN-α Protein

C. Dinney, R. Connor, W. Benedict, 2004 .

Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer.

C. Dinney, W. Benedict, M. Munsell, 2007, The Journal of urology.

Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy

Y. Lotan, C. Dinney, T. Morgan, 2018, World Journal of Urology.

The impact of variant histology on the outcome of bladder cancer treated with curative intent.

C. Dinney, P. Black, G. Brown, 2009, Urologic oncology.

Suppression of human bladder cancer growth by increased expression of C-CAM1 gene in an orthotopic model.

C. Dinney, S. H. Lin, W. Zhang, 1996, Cancer research.

Energy Balance, the PI3K-AKT-mTOR Pathway Genes, and the Risk of Bladder Cancer

Xifeng Wu, H. Grossman, C. Dinney, 2010, Cancer Prevention Research.

Energy Balance , the PI 3 K-AKT-mTOR Pathway Genes , and the Risk of Bladder Cancer

Xifeng Wu, H. Grossman, C. Dinney, 2010 .

Urachal carcinoma: a pathologic and clinical study of 46 cases.

B. Czerniak, C. Dinney, Charles C. Guo, 2015, Human pathology.

Clinical outcomes of cT1 micropapillary bladder cancer.

B. Czerniak, S. Parikh, C. Dinney, 2015, The Journal of urology.

Differential expression of GATA-3 in urothelial carcinoma variants.

B. Czerniak, C. Dinney, Charles C. Guo, 2014, Human pathology.

Refining patient selection for neoadjuvant chemotherapy before radical cystectomy.

R. Millikan, S. Groshen, B. Czerniak, 2014, The Journal of urology.

Cancer risk associated with chronic diseases and disease markers: prospective cohort study

Xifeng Wu, W. Chow, Y. Ye, 2018, British Medical Journal.

Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer: Results from a Multi-Institutional Experience

G. Haber, R. Thompson, S. Boorjian, 2021, The Journal of urology.

Detection of Bladder Cancer Using Proteomic Profiling of Urine Sediments

H. Grossman, B. Czerniak, C. Dinney, 2012, PloS one.

Use of Fluorescence in situ Hybridization to Predict Patient Response to BCG Therapy for Bladder Cancer: Results of a Prospective Trial

C. Dinney, A. Kamat, R. Katz, 2012 .

Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.

C. Dinney, S. Porten, A. Kamat, 2017, European urology focus.

Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi.

C. Wood, S. Swisher, C. Dinney, 2003, Urologic oncology.

Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer.

B. Czerniak, C. Dinney, W. Benedict, 1997, International journal of radiation oncology, biology, physics.

Preoperative radiotherapy for muscle‐invasive bladder carcinoma. Long term follow‐up and prognostic factors for 338 patients

C. Dinney, A. V. von Eschenbach, A. Pollack, 1994, Cancer.

Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone.

C. Dinney, A. V. von Eschenbach, A. Pollack, 1995, International journal of radiation oncology, biology, physics.

Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience.

S. Parikh, C. Dinney, A. Kamat, 2016, Urologic oncology.

Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy.

Y. Lotan, G. Sonpavde, C. Dinney, 2011, The Journal of urology.

Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers.

C. Dinney, A. Kamat, J. Shah, 2020, Urologic oncology.

Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer?

C. Dinney, D. McConkey, M. Bar‐eli, 2008, The Journal of urology.

Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE)

C. Dinney, D. McConkey, R. Highshaw, 2004, Current opinion in urology.

Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette–Guérin

Xifeng Wu, C. Dinney, D. Chang, 2017, Oncotarget.

Malnutrition and overall survival in older patients with cancer.

V. Valero, C. Dinney, D. Tripathy, 2018, Clinical nutrition.

Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy.

H. Grossman, C. Dinney, S. Matin, 2010, Urology.

Cardiac history and risk of post-cystectomy cardiac complications.

H. Grossman, C. Dinney, S. Matin, 2009, Urology.

Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center

C. Dinney, A. Kamat, P. Hensley, 2021, World Journal of Urology.

Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study.

Xifeng Wu, H. Grossman, Y. Ye, 2018, The American journal of clinical nutrition.

The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside

C. Dinney, D. McConkey, J. Duplisea, 2018, World Journal of Urology.

Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.

K. Ogan, Y. Lotan, S. Boorjian, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice.

C. Bucana, C. Dinney, I. Fidler, 1995, The Journal of urology.

Characterization of initiation of angiogenesis in early stages of prostate adenocarcinoma development and progression in a transgenic murine model.

J. Chin, C. Dinney, M. Moussa, 2004, Urology.

Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.

C. Dinney, D. McConkey, Simon A. Williams, 2005, Cancer research.

Novel therapeutics for patients with non-muscle-invasive bladder cancer

C. Dinney, A. Kamat, R. Svatek, 2009, Expert review of anticancer therapy.

Original Articles: Bladder Cancer: Management of Transitional Cell Carcinoma Involving Von Brunn's Nests

C. Dinney, R. Babaian, A. V. von Eschenbach, 1995 .

Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer.

Anirban P. Mitra, C. Dinney, A. Mitra, 2020, European urology.

Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index.

V. Valero, C. Dinney, D. Tripathy, 2018, Journal of geriatric oncology.

Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and bladder cancer risk

Xifeng Wu, H. Grossman, C. Dinney, 2007, International journal of cancer.

Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Interferon-Induced Apoptosis in Human Bladder Cancer Cells

R. Millikan, H. Grossman, C. Dinney, 2004, Cancer Research.

The use of urine-based biomarkers in bladder cancer.

V. Reuter, H. Grossman, M. Blute, 2006, Urology.

Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus.

C. Dinney, J. Nesbitt, D. Schrump, 1997, The Annals of thoracic surgery.

Effects of thiazolidinedione in patients with active bladder cancer

C. Dinney, D. McConkey, A. Kamat, 2018, BJU international.

Inhibition of Growth and Metastasis of Orthotopic Human Prostate Cancer in Athymic Mice by Combination Therapy with Pegylated Interferon-- 2 b and Docetaxel

C. Bucana, C. Dinney, I. Fidler, 2002 .

Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.

C. Dinney, W. Benedict, T. Karashima, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter.

P. Tamboli, C. Dinney, T. Shuin, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice.

C. Dinney, I. Fidler, C. Baker, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel.

C. Bucana, C. Dinney, I. Fidler, 2002, Cancer research.

Genetic instability in bladder cancer assessed by the comet assay.

M. Spitz, Xifeng Wu, Kerang Zhang, 2003, Journal of the National Cancer Institute.

Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy.

H. Grossman, C. Dinney, M. Munsell, 2009, Urology.

Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy.

R. Millikan, B. Czerniak, C. Dinney, 2004, The Journal of urology.

Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?

R. Millikan, H. Grossman, C. Wood, 2003, The Journal of urology.

Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC.

R. Millikan, C. Dinney, C. Logothetis, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

p53 and RB expression predict progression in T1 bladder cancer.

C. Dinney, W. F. Benedict, J. Palmer, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Controversies in ilioinguinal lymphadenectomy.

C. Dinney, C. Pettaway, P. Hegarty, 2010, The Urologic clinics of North America.

Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high‐risk upper tract transitional cell carcinoma

R. Millikan, V. Margulis, C. Wood, 2010, Cancer.

Survival outcomes in patients undergoing neoadjuvant chemotherapy for upper tract urothelial cell carcinoma.

C. Dinney, S. Matin, A. Kamat, 2013, Journal of Clinical Oncology.

Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center.

R. Millikan, C. Dinney, S. Matin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer.

Xifeng Wu, C. Wood, C. Dinney, 2007, The Journal of urology.

Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy.

C. Dinney, A. Siefker-Radtke, R. Svatek, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Neoadjuvant chemotherapy for bladder cancer

H. Grossman, C. Dinney, P. Black, 2006, World Journal of Urology.

Therapy of invasive bladder cancer.

C. Dinney, 2006, Urology.

Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder.

H. Grossman, B. Czerniak, C. Dinney, 2001, Oncology reports.

Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy.

B. Czerniak, C. Dinney, W. Benedict, 1996, Urology.

Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer.

Y. Lotan, A. Sagalowsky, G. Sonpavde, 2011, The Journal of urology.

Surveillance and management of recurrence for upper tract transitional cell carcinoma.

C. Dinney, M. Droller, S. Canfield, 2003, The Urologic clinics of North America.

Nephrectomy and vena caval thrombectomy in patients with metastatic renal cell carcinoma.

C. Dinney, J. Nesbitt, L. Pisters, 1997, Urology.

Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy.

C. Dinney, M. Munsell, A. Kamat, 2006, The Journal of urology.

Table of Contents

F. Montorsi, L. Edenbrandt, P. Tamboli, 2016 .

Novel fluorescence in situ hybridization‐based definition of bacille Calmette‐Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies

Xifeng Wu, C. Dinney, A. Kamat, 2016, BJU international.

Management of urethral recurrence after orthotopic urinary diversion

C. Dinney, M. Munsell, A. Kamat, 2009, BJU international.

Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer

B. Czerniak, C. Dinney, A. Kamat, 2010, Cancer.

Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation

C. Dinney, R. Connor, W. Benedict, 2006, Cancer Gene Therapy.

Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma.

B. Czerniak, C. Dinney, Jianjun Gao, 2022, Urologic oncology.

ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder.

M. Babjuk, Sam S. Chang, J. Witjes, 2013, European urology.

Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis.

C. Dinney, A. Kamat, X. Wang, 2020, The journal of sexual medicine.

GENETIC VARIANTS WITHIN THE WNT/ β -CATENIN SIGNALING PATHWAY AS INDICATORS OF BLADDER CANCER RISK

Xifeng Wu, Y. Ye, C. Dinney, 2016 .

Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434 – 5

Mauro A. A. Castro, K. Hoadley, N. Malats, 2019 .

The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma.

R. Millikan, C. Dinney, A. Kamat, 2006, The Journal of urology.

Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or gamma-interferon.

C. Dinney, I. Fidler, A. V. von Eschenbach, 1992, Cancer research.

Personal Permanent Hair Dye Use Is Not Associated with Bladder Cancer Risk: Evidence from a Case-Control Study

Xifeng Wu, H. Grossman, C. Dinney, 2006, Cancer Epidemiology Biomarkers & Prevention.

The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer.

S. Parikh, C. Dinney, S. Matin, 2012, Urologic oncology.

Organ-site dependence for the production of urokinase-type plasminogen activator and metastasis by human renal cell carcinoma cells.

C. Bucana, C. Dinney, I. Fidler, 1997, The American journal of pathology.

Accuracy of High-Frequency Endoluminal Ultrasonography for Clinical Staging of Upper Tract Urothelial Carcinoma.

R. Vikram, A. Rao, C. Dinney, 2018, Journal of endourology.

Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide.

C. Bucana, C. Dinney, R. Radinsky, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Matrix metalloproteinase polymorphisms and bladder cancer risk.

J. Gu, Xifeng Wu, H. Grossman, 2006, Cancer research.

Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder.

H. Grossman, C. Dinney, R. Veltri, 1998, The Journal of urology.

Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer.

C. Dinney, M. Munsell, D. McConkey, 2011, The Journal of urology.

Risk assessment of renal cell carcinoma using alkaline comet assay

Hushan Yang, Xifeng Wu, C. Wood, 2007, Cancer.

Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin.

C. Dinney, L. Pagliaro, P. Perrotte, 2003, Urologic oncology.

Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma.

C. Dinney, J. Slaton, D. Swanson, 1998, The Journal of urology.

Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort.

C. Dinney, A. Kamat, W. Qiao, 2020, European urology focus.

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.

G. Andriole, Y. Lotan, S. Boorjian, 2020, The Lancet. Oncology.

Clinical Scenario: Initial CIS

C. Dinney, S. Porten, 2015 .

A Genome-Wide Association Study Identifies a Locus on Chromosome 14q21 as a Predictor of Leukocyte Telomere Length and as a Marker of Susceptibility for Bladder Cancer

S. Shete, J. Gu, Xifeng Wu, 2011, Cancer Prevention Research.

Repeated I ntravesical I nstillations o f a n A denoviral V ector i n Patients W ith L ocally A dvanced B ladder C ancer: A P hase I Study o f p53 Gene T herapy

C. Dinney, L. Pagliaro, J. Slaton, 2003 .

High-grade neuroendocrine carcinoma of the urachus-report of 3 cases.

B. Czerniak, C. Dinney, P. Troncoso, 2017, Human pathology.

Should chemotherapy still be used to treat all muscle invasive bladder cancer in the “era of immunotherapy”?

C. Dinney, J. Duplisea, 2019, Expert review of anticancer therapy.

Lymphoepithelioma‐like Carcinoma of the Urinary Bladder

M. Gulley, C. Dinney, M. Amin, 1994, The American journal of surgical pathology.

Lymphoepithelioma of the bladder: a clinicopathological study of 3 cases.

C. Dinney, R. Babaian, D. Johnson, 1993, The Journal of urology.

Lentiviral interferon: A novel method for gene therapy in bladder cancer

Anirban P. Mitra, B. Czerniak, C. Dinney, 2018, Molecular therapy oncolytics.

P53 in bladder cancer: mechanism of action, prognostic value, and target for therapy.

C. Dinney, W. Benedict, J. Slaton, 2001, Urology.

Salvage prostatectomy with continent catheterizable urinary reconstruction: a novel approach to recurrent prostate cancer after radiation therapy.

C. Dinney, L. Pisters, E. McGuire, 2000, The Journal of urology.

Roles of tumor suppressor and telomere maintenance genes in cancer and aging--an epidemiological study.

M. Spitz, J. Gu, Xifeng Wu, 2005, Carcinogenesis.

Genome-Wide Association Study Identifies Variants in Casein Kinase II (CSNK2A2) to be Associated With Leukocyte Telomere Length in a Punjabi Sikh Diabetic Cohort

T. Spector, J. Lane, N. Samani, 2014, Circulation. Cardiovascular genetics.

Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy.

H. Grossman, C. Dinney, S. Matin, 2007, Urology.

Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm?

C. Wood, C. Dinney, S. Matin, 2006, BJU international.

Multicenter evaluation of neoadjuvant and induction gemcitabine–carboplatin versus gemcitabine–cisplatin followed by radical cystectomy for muscle-invasive bladder cancer

Y. Lotan, C. Dinney, T. Morgan, 2022, World Journal of Urology.

Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer.

K. Baggerly, B. Czerniak, C. Dinney, 2008, The Journal of urology.

THE MITOTOIC SPINDLE APPARATUS INHIBITOR AZD4877 HOLDS PROMISE AS A NOVEL THERAPEUTIC OPTION AGAINST HUMAN BLADDER CANCER

C. Dinney, D. McConkey, J. Shah, 2009 .

Seminar article BCAN Think Tank session 1: Overview of risks for and causes of bladder cancer 1

C. Dinney, B. Bochner, A. Zlotta, 2010 .

Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy

C. Dinney, Jianjun Gao, A. Kamat, 2018, BJU international.

Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette–Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer

H. Grossman, C. Dinney, W. Benedict, 2016, Annals of Surgical Oncology.

Bladder Cancer Involving Smooth Muscle of Indeterminate Type or Muscularis Mucosae in Transurethral Biopsy Specimens.

B. Czerniak, C. Dinney, Charles C. Guo, 2020, American journal of clinical pathology.

Should patients with non‐muscle‐invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette–Guérin?

C. Dinney, A. Kamat, P. Hensley, 2021, BJU international.

The importance of orthotopic implantation to the isolation and biological characterization of a metastatic human clear cell renal-carcinoma in nude-mice.

C. Dinney, I. Fidler, S. Pathak, 1993, International journal of oncology.

All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors

C. Dinney, Charles C. Guo, A. Kamat, 2022, The Journal of urology.

The Role of Fluorescence in Situ Hybridization for Predicting Recurrence after Adjuvant Bacillus Calmette-Guérin in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer Patients: A Systematic Review and Meta-Analysis of Individual Patient Data.

T. D. de Reijke, L. Bubendorf, C. Dinney, 2020, The Journal of urology.

High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette–Guerin therapy: A long-term survival analysis

J. Gu, Xifeng Wu, Y. Ye, 2017, Oncoimmunology.

Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.

C. Dinney, D. Hicklin, K. Inoue, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Micropapillary bladder cancer: current treatment patterns and review of the literature.

E. Messing, E. Plimack, C. Dinney, 2014, Urologic oncology.

Interferon-α Induces TRAIL Expression and Cell Death Via an IRF-1-Dependent Mechanism in Human Bladder Cancer Cells

C. Dinney, D. McConkey, A. Papageorgiou, 2007 .

Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin.

C. Dinney, R. Sylvester, A. Kamat, 2021, European urology oncology.

Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases.

P. Tamboli, B. Czerniak, C. Dinney, 2009, Human pathology.

A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging

M. Gleave, L. Fazli, B. Hadaschik, 2007, BJU international.

Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression.

B. Czerniak, C. Dinney, Tadeusz Majewski, 2010, Urologic oncology.

Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis.

R. Millikan, B. Czerniak, C. Dinney, 2013, The Journal of urology.

Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer.

Hushan Yang, Xifeng Wu, H. Grossman, 2006, Carcinogenesis.

Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy

F. Montorsi, Y. Lotan, C. Dinney, 2012, World Journal of Urology.

Therapy and prognosis for male anterior urethral carcinoma: an update.

C. Dinney, R. Babaian, A. V. von Eschenbach, 1994, Urology.

Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.

C. Dinney, A. Kamat, D. Urbauer, 2016, European urology.

Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial.

Xifeng Wu, C. Dinney, A. Kamat, 2012, The Journal of urology.

Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials

C. Drake, C. Dinney, J. McKiernan, 2019, Clinical Cancer Research.

Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration

C. Dinney, A. Kamat, J. Kawedia, 2017, Drugs in R&D.

Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry.

Zhaoming, Jack A. Taylor, L. Kiemeney, 2016, Human molecular genetics.

Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancer.

Xifeng Wu, Y. Ye, C. Dinney, 2013, Carcinogenesis.

Genetic Variations in the Sonic Hedgehog Pathway Affect Clinical Outcomes in Non–Muscle-Invasive Bladder Cancer

N. Malats, A. Picornell, M. Kogevinas, 2010, Cancer Prevention Research.

Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants.

B. Czerniak, C. Dinney, S. Matin, 2014, American journal of clinical pathology.

Vitamins C and K3 sensitize human urothelial tumors to gemcitabine.

C. Dinney, A. Kamat, W. Kassouf, 2006, The Journal of urology.

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

P. Sharma, C. Dinney, Jianjun Gao, 2020, Nature Medicine.

Deoxyribonucleic acid ploidy enhances the cytological prediction of recurrent transitional cell carcinoma of the bladder.

H. Grossman, C. Dinney, J. Slaton, 1997, The Journal of urology.

Urine cell-based DNA methylation classifier for monitoring bladder cancer

L. Kiemeney, B. Czerniak, J. Witjes, 2018, Clinical Epigenetics.

Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.

C. Dinney, D. Hicklin, K. Inoue, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer.

C. Dinney, K. Inoue, M. Bar‐eli, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer

C. Dinney, D. McConkey, A. Kamat, 2009, Cancer and Metastasis Reviews.

Pathway analysis of bladder cancer genome-wide association study identifies novel pathways involved in bladder cancer development

D. Silverman, N. Rothman, S. Chanock, 2016, Genes & cancer.

Intrinsic subtypes and bladder cancer metastasis

C. Dinney, D. McConkey, W. Choi, 2016, Asian journal of urology.

Summary and Recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer

S. Groshen, C. Tangen, C. Drake, 2016, Bladder cancer.

The origin of bladder cancer from mucosal field effects

Khanh N. Dinh, J. Weinstein, D. Cogdell, 2021, bioRxiv.

Focus on bladder cancer.

R. Millikan, A. Sabichi, Xifeng Wu, 2004, Cancer cell.

The p63 Protein Isoform ΔNp63α Inhibits Epithelial-Mesenchymal Transition in Human Bladder Cancer Cells

B. Czerniak, C. Dinney, D. McConkey, 2012, The Journal of Biological Chemistry.

Serum microRNAs as predictors of risk for non-muscle invasive bladder cancer

Xifeng Wu, Y. Ye, C. Dinney, 2018, Oncotarget.

Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.

C. Collins, C. Dinney, J. Wright, 2016, Urologic oncology.

miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy

Woonyoung Choi, Liana Adam, G. Calin, 2009, Clinical Cancer Research.

Origins of Bladder Cancer.

B. Czerniak, C. Dinney, D. McConkey, 2016, Annual review of pathology.

Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy

K. Baggerly, D. Yoon, S. Scherer, 2008, Laboratory Investigation.

Genetic polymorphism in bladder cancer.

J. Gu, Xifeng Wu, H. Grossman, 2007, Frontiers in bioscience : a journal and virtual library.

Metastatic model for human prostate cancer using orthotopic implantation in nude mice.

C. Dinney, I. Fidler, N. Ordóñez, 1992, Journal of the National Cancer Institute.

Plasma microRNA profiles for bladder cancer detection.

Wang Jing, Alexander Zien, Lixia Diao, 2013, Urologic oncology.

Clinical model of lifetime cost of treating bladder cancer and associated complications.

A. Sabichi, H. Grossman, C. Dinney, 2006, Urology.

Genetic Variations in the Transforming Growth Factor Beta Pathway as Predictors of Bladder Cancer Risk

Xifeng Wu, Y. Ye, C. Dinney, 2012, PloS one.

Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells

C. Dinney, D. McConkey, B. Davies, 2012, Cancer biology & therapy.

Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk.

J. Gu, Hushan Yang, Xifeng Wu, 2009, Carcinogenesis.

Genetic variations in PI 3 K-AKT-mTOR pathway and bladder cancer risk

J. Gu, Hushan Yang, Xifeng Wu, 2009 .

Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer.

C. Dinney, K. Inoue, M. Bar‐eli, 2000, Cancer research.

High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk.

J. Gu, Xifeng Wu, H. Grossman, 2007, Carcinogenesis.

High-Order Interactions among Genetic Variants in DNA Base Excision Repair Pathway Genes and Smoking in Bladder Cancer Susceptibility

Xifeng Wu, H. Grossman, C. Dinney, 2007, Cancer Epidemiology Biomarkers & Prevention.

Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.

C. Dinney, G. Steinberg, R. Greenberg, 2013, Urologic oncology.

The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors.

C. Dinney, M. Rosenblum, P. Sweeney, 2005, Neoplasia.

Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients.

J. Gu, Xifeng Wu, C. Dinney, 2010, Carcinogenesis.

Genome-wide association study identifies multiple loci associated with bladder cancer risk.

William Wheeler, Paolo Vineis, Peter Kraft, 2014, Human molecular genetics.

The role of angiogenesis in prostate and other urologic cancers: a review.

C. Dinney, J. Izawa, 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Bladder cancer angiogenesis and metastasis—translation from murine model to clinical trial

C. Dinney, P. Black, 2007, Cancer and Metastasis Reviews.

Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor.

C. Dinney, I. Fidler, K. Inoue, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer.

P. Thall, R. Millikan, C. Dinney, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer

B. Czerniak, C. Dinney, J. Bondaruk, 2013, Molecular Cancer Therapeutics.

Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use

J. Weinstein, K. Baggerly, D. Cogdell, 2016, EBioMedicine.

Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse

C. Dinney, L. Pagliaro, P. Perrotte, 1999, Cancer Gene Therapy.

Genetic subtypes of invasive bladder cancer

C. Dinney, D. McConkey, W. Choi, 2015, Current opinion in urology.

Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer.

B. Czerniak, C. Dinney, D. McConkey, 2015, Hematology/oncology clinics of North America.

Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center.

R. Millikan, H. Grossman, C. Dinney, 2013, European urology.

Small Cell Urothelial Carcinoma

A. Parwani, C. Dinney, A. Siefker-Radtke, 2012 .

Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience.

R. Millikan, H. Grossman, C. Dinney, 2004, The Journal of urology.

Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta.

C. Bucana, C. Dinney, I. Fidler, 1999, Cancer research.

Therapy of locally recurrent renal cell carcinoma after nephrectomy.

C. Dinney, L. Pisters, S. Tanguay, 1996, The Journal of urology.

Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder

B. Czerniak, C. Dinney, M. Munsell, 2007, Cancer.

Genetic Variants in Telomere-Maintenance Genes and Bladder Cancer Risk

J. Gu, Xifeng Wu, C. Dinney, 2012, PloS one.

Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer

B. Czerniak, C. Dinney, R. Connor, 2002, Cancer Gene Therapy.

Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease.

C. Dinney, A. Kamat, Roger Li, 2019, European urology.

The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non‐muscle‐invasive bladder cancer treated with bacillus Calmette–Guérin

C. Dinney, Jianjun Gao, Yu Shen, 2020, BJU International.

Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration.

C. Bucana, C. Dinney, I. Fidler, 1998, Cancer research.

Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer

Jian Gu, Yuanqing Ye, Xifeng Wu, 2008, Cancer.

Time interval from transurethral resection of bladder tumour to bacille Calmette–Guérin induction does not impact therapeutic response

C. Dinney, A. Kamat, Roger Li, 2021, BJU international.

In situ activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CGP 31362

C. Dinney, I. Fidler, J. Killion, 1991, Cancer Immunology, Immunotherapy.

Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor.

C. Wood, C. Dinney, K. Inoue, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Biosafety of in vivo adenovirus-p53 intravesical administration in mice.

R. Price, C. Dinney, D. R. Wilson, 2000, Urology.

Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol. In press.

Mauro A. A. Castro, J. Weinstein, K. Hoadley, 2020, European urology.

Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer.

Yuanqing Ye, Xifeng Wu, Hushan Yang, 2008, Cancer research.

Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection.

Yair Lotan, Hiroshi Katayama, Subrata Sen, 2008, Journal of the National Cancer Institute.

Growth factors and receptors as prognostic markers in urothelial carcinoma

C. Dinney, P. Black, 2008, Current urology reports.

Targeted therapies in bladder cancer--an update.

C. Dinney, P. Black, P. Agarwal, 2007, Urologic oncology.

A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.

R. Millikan, B. Czerniak, C. Dinney, 2016, European urology.

Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer

C. Dinney, I. Jayaratna, N. Navai, 2015, Translational andrology and urology.

Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center.

R. Millikan, C. Dinney, S. Matin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rationale for bladder‐sparing surgery in patients with locally advanced colorectal carcinoma

C. Dinney, J. Skibber, J. Slaton, 1999, Cancer.

Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival.

R. Millikan, J. Gu, Xifeng Wu, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers

C. Dinney, Yu Shen, D. McConkey, 2012, PloS one.

Combination therapy with IFN-α plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells

C. Dinney, W. Benedict, D. McConkey, 2006, Molecular Cancer Therapeutics.

Multilevel-analysis identify a cis-expression quantitative trait locus associated with risk of renal cell carcinoma

N. Rothman, S. Chanock, Xifeng Wu, 2015 .

Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder.

Y. Lotan, A. Sagalowsky, C. Dinney, 2013, Urologic oncology.

Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC.

C. Dinney, M. Munsell, P. Spiess, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy.

R. Millikan, C. Dinney, K. Inoue, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.

C. Dinney, D. Hicklin, K. Inoue, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Generation of patient‐derived xenografts from fine needle aspirates or core needle biopsy

S. Swisher, C. Dinney, J. Gershenwald, 2017, Surgery.

Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study.

J. Patard, J. Lam, R. Figlin, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population.

R. Figlin, A. Belldegrun, C. Wood, 2003, The Journal of urology.

Benzo(a)pyrene Diol Epoxide-Induced Chromosome 9p21 Aberrations Are Associated with Increased Risk of Bladder Cancer

Xifeng Wu, C. Dinney, Y. Horikawa, 2008, Cancer Epidemiology Biomarkers & Prevention.

Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.

C. Dinney, J. Bellmunt, M. Hussain, 2003, Critical reviews in oncology/hematology.

1240: Prospective Evidence Supporting the Utility of Neooadjuvant Chemotherapy in Small Cell Urothelial Cancer: Preliminary Results from A Phase II Clinical Trial at the M.D. Anderson Cancer Center

R. Millikan, C. Dinney, A. Kamat, 2006 .

The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy.

Y. Lotan, C. Dinney, T. Morgan, 2019, Urologic oncology.

PD12-07 A PHASE III STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC FOR PATIENTS WITH HIGH-GRADE, BCG UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER

S. Boorjian, C. Dinney, 2020 .

Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer.

C. Dinney, W. Kassouf, L. Adam, 2006, The Journal of urology.

Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.

Liana Adam, Wassim Kassouf, C. Dinney, 2005, Cancer research.

Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukin-8.

C. Wood, C. Dinney, K. Inoue, 2001, Oncology reports.

Multi‐targeted agents in the treatment of urothelial carcinoma

G. Sonpavde, C. Dinney, N. Hahn, 2015 .

Safety and efficacy of intravesical nadofaragene firadenovec for patients with high-grade, BCG unresponsive nonmuscle invasive bladder cancer (NMIBC): Results from a phase III trial.

S. Boorjian, C. Dinney, 2020 .

Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.

C. Dinney, D. Hicklin, T. Shuin, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but Not Therapeutic

C. Dinney, Yu Shen, A. Kamat, 2022, The Journal of urology.

Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Yair Lotan, Todd M Morgan, Joshua Griffin, 2015, European urology.

p63 expression correlates with sensitivity to the Eg5 inhibitor AZD4877 in bladder cancer cells

C. Dinney, D. McConkey, A. Siefker-Radtke, 2012, Cancer biology & therapy.

Micropapillary bladder cancer

P. Tamboli, C. Dinney, A. Kamat, 2007, Cancer.

Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer.

C. Dinney, M. Milowsky, D. Bajorin, 2019, JAMA oncology.

WHAT WOMEN WANT: RADICAL CYSTECTOMY AND PERIOPERATIVE SEXUAL FUNCTION EDUCATIONAL NEEDS.

C. Dinney, A. Kamat, X. Wang, 2021, Urology.

Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy

C. Dinney, A. Kamat, J. Shah, 2018, Surgical innovation.

The role of radical cystectomy in patients with clinical T4b bladder cancer.

C. Dinney, M. Munsell, A. Kamat, 2011, Urologic oncology.

Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients.

Y. Lotan, A. Sagalowsky, C. Dinney, 2010, The Journal of urology.

Complications of radical cystectomy: impact of the timing of perioperative chemotherapy.

C. Dinney, D. Swanson, M. Hall, 1996, Urology.

Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.

C. Dinney, D. Hicklin, B. Mian, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Anti-Vascular Endothelial Growth Factor Receptor 2 Antibody Reduces Tumorigenicity and Metastasis in Orthotopic Prostate Cancer Xenografts via Induction of Endothelial Cell Apoptosis and Reduction of Endothelial Cell Matrix Metalloproteinase Type 9 Production 1

C. Dinney, D. Hicklin, B. Mian, 2002 .

12th Annual meeting of the Society of Urologic Oncology (SUO) bladder cancer sessions I and II summary report.

Y. Lotan, Sam S. Chang, J. Gore, 2012, Urologic oncology.

Projecting individualized probabilities of developing bladder cancer in white individuals.

M. Spitz, J. Gu, Xifeng Wu, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bladder cancer risk as modified by family history and smoking

M. Spitz, Xifeng Wu, C. Dinney, 2006, Cancer.

Fibroblast Growth Factor Receptors-1 and -3 Play Distinct Roles in the Regulation of Bladder Cancer Growth and Metastasis: Implications for Therapeutic Targeting

C. Dinney, D. McConkey, P. Black, 2013, PloS one.

Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach?

K. Do, B. Czerniak, C. Dinney, 2006, Urology.

Should cystectomy only be performed at high-volume hospitals by high-volume surgeons?

C. Dinney, P. Black, G. Brown, 2006, Current opinion in urology.

Inhibition of tumor growth by systemic treatment with thrombospondin‐1 peptide mimetics

C. Dinney, O. Volpert, N. Bouck, 2002, International journal of cancer.

Molecular correlates of gefitinib responsiveness in human bladder cancer cells

C. Dinney, M. Pino, D. McConkey, 2007, Molecular Cancer Therapeutics.

Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma.

C. Dinney, J. Slaton, D. Swanson, 1998, The Journal of urology.

Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma

V. Margulis, E. Jonasch, C. Wood, 2014, Cancer.

Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy

C. Dinney, Jianjun Gao, A. Kamat, 2021, The Journal of urology.

Unique somatic variants in the DNA from urine exosomes of bladder cancer patients

T. Gilliam, M. D'Souza, N. Maltsev, 2021 .

Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma

Y. Qi, B. Czerniak, C. Dinney, 2021, The Journal of urology.

Genetic Variants in the Wnt/β-Catenin Signaling Pathway as Indicators of Bladder Cancer Risk.

Xifeng Wu, Y. Ye, C. Dinney, 2015, The Journal of urology.

A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3.

Jian Gu, Nilanjan Chatterjee, Jonine D Figueroa, 2011, Human molecular genetics.

Dietary Intake of Vegetables and Fruits and the Modification Effects of GSTM1 and NAT2 Genotypes on Bladder Cancer Risk

J. Gu, Xifeng Wu, C. Dinney, 2009, Cancer Epidemiology Biomarkers & Prevention.

Profiling of Genetic Variations in Inflammation Pathway Genes in Relation to Bladder Cancer Predisposition

J. Gu, Hushan Yang, Xifeng Wu, 2008, Clinical Cancer Research.

Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes.

R. Millikan, M. Spitz, J. Gu, 2006, American journal of human genetics.

Analysis of imaging modalities, staging systems, and prognostic indicators for renal cell carcinoma.

C. Dinney, J. Gajewski, P. Belitsky, 1992, Urology.

Intake of red meat and heterocyclic amines, metabolic pathway genes and bladder cancer risk

Xifeng Wu, H. Grossman, C. Dinney, 2012, International journal of cancer.

Clinical model of cost of bladder cancer in the elderly.

A. Sabichi, H. Grossman, C. Dinney, 2008, Urology.

Correlation between annual volume of cystectomy, professional staffing, and outcomes

C. Dinney, L. Elting, B. Bekele, 2005, Cancer.

The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence.

J. Gu, Xifeng Wu, H. Grossman, 2005, Pharmacogenomics.

Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder.

C. Dinney, J. Wright, D. Lin, 2007, The Journal of urology.

Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer

B. Czerniak, C. Dinney, X. Su, 2016, Oncotarget.

Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer

Y. Lotan, C. Dinney, T. Morgan, 2021, World Journal of Urology.

Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium.

Y. Lotan, C. Dinney, T. Morgan, 2020, European urology focus.

Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer.

Y. Lotan, C. Dinney, T. Morgan, 2020, Urologic oncology.

Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells

Xifeng Wu, C. Dinney, D. Theodorescu, 2008, Clinical Cancer Research.

The International Bladder Cancer Network.

C. Dinney, B. Schmitz-Dräger, P. Goebell, 2010, Urologic oncology.

Clinical and therapeutic significance of aberrant differentiation patterns in bladder cancer

C. Dinney, P. Black, G. Brown, 2007, Expert review of anticancer therapy.

BCAN Think Tank session 1: Overview of risks for and causes of bladder cancer.

T. H. van der Kwast, C. Dinney, B. Bochner, 2010, Urologic oncology.

TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer

B. Broom, B. Czerniak, C. Dinney, 2020, Molecular Cancer Research.

Upper urinary tract tumors with nontransitional histology: a single-center experience.

H. Grossman, P. Tamboli, C. Dinney, 2006, Urology.

Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule.

C. Dinney, I. Fidler, K. Inoue, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Nucleotide Excision Repair Gene Polymorphisms and Recurrence after Treatment for Superficial Bladder Cancer

J. Gu, Xifeng Wu, C. Dinney, 2005, Clinical Cancer Research.

Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort

C. Dinney, S. Shariat, P. Karakiewicz, 2011, BJU international.

International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy

U. Capitanio, Y. Lotan, A. Sagalowsky, 2010, BJU international.

P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors.

C. Dinney, M. Munsell, P. Spiess, 2007, European urology.

Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project.

S. Groshen, F. Waldman, C. Cordon-Cardo, 2021, Urologic oncology.

The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.

R. Millikan, C. Dinney, D. McConkey, 2004, Molecular cancer therapeutics.

Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.

C. Dinney, K. Inoue, T. Shuin, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.

E. Petricoin, S. Groshen, F. Waldman, 2014, Urologic oncology.

Comprehensive pathway‐based interrogation of genetic variations in the nucleotide excision DNA repair pathway and risk of bladder cancer

S. Shete, J. Gu, C. Dinney, 2012, Cancer.

Salvage topical therapy for upper tract urothelial carcinoma

C. Wood, C. Dinney, John W. Davis, 2018, World Journal of Urology.

Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer

B. Czerniak, S. Parikh, C. Dinney, 2017, BJU international.

Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation

C. Dinney, D. McConkey, J. Duplisea, 2019, Oncoimmunology.

Seminar article Targeted therapies in bladder cancer—an update

C. Dinney, P. Black, P. Agarwal, 2007 .

Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis.

Y. Lotan, C. Dinney, T. Curiel, 2014, Urology.

Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video‐endoscopic inguinal lymphadenectomy in patients with penile carcinoma

C. Wood, C. Dinney, S. Matin, 2013, BJU international.

Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis

B. Czerniak, C. Dinney, D. McConkey, 2016, Oncotarget.

Mice by Systemic Interferon-Angiogenesis , and Growth of Human Bladder Carcinoma in Inhibition of Basic Fibroblast Growth Factor Expression

C. Dinney, I. Fidler, P. Perrotte, 2006 .

Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG

C. Dinney, S. Lerner, G. Steinberg, 2015, Bladder cancer.

Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy

C. Dinney, M. Munsell, A. Kamat, 2012, BJU international.

New Strategies in Muscle-Invasive Bladder Cancer: On the Road to Personalized Medicine

C. Dinney, D. McConkey, J. Shah, 2011, Clinical Cancer Research.

Clinical Cancer esearch cer Therapy : Clinical Effectiveness of Off-Protocol Adjuvant Chemotherapy for R ients with Urothelial Carcinoma of the Urinary Bladder

R. Millikan, A. Sagalowsky, C. Dinney, 2010 .

If cystectomy is insufficient, what is an urologist to do?

H. Grossman, C. Dinney, H. B. Grossman, 2003, Urologic oncology.

The relationship of local control to distant metastasis in muscle invasive bladder cancer.

H. Grossman, C. Dinney, A. Pollack, 1995, The Journal of urology.

Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma.

C. Dinney, C. Logothetis, A. V. von Eschenbach, 1996, The Journal of urology.

Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy.

C. Dinney, S. Matin, A. Kamat, 2011, Urology.

Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma.

B. Czerniak, C. Dinney, S. Matin, 2019, Urologic oncology.

OUTCOMES OF NON-METASTATIC MICROPAPILLARY VARIANT UPPER TRACT UROTHELIAL CARCINOMA

B. Czerniak, C. Dinney, S. Matin, 2019 .

Dietary patterns and risk of recurrence and progression in non‐muscle‐invasive bladder cancer

L. Kiemeney, Xifeng Wu, Y. Ye, 2018, International journal of cancer.

Emerging drugs for targeted therapy of bladder cancer

C. Dinney, D. McConkey, P. Black, 2007, Expert opinion on emerging drugs.

Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience.

C. Wood, C. Dinney, P. Spiess, 2006, The Journal of urology.

Laparoscopy and Robotics Perioperative Outcomes of Laparoscopic Radical Nephroureterectomy and Regional Lymphadenectomy in Patients With Upper Urinary Tract Urothelial Carcinoma After Neoadjuvant Chemotherapy

C. Dinney, S. Matin, A. Kamat, 2011 .

Delayed ureterectomy after incomplete nephroureterectomy for upper tract urothelial carcinoma: pathologic findings and outcomes.

C. Dinney, S. Matin, A. Kamat, 2013, International braz j urol : official journal of the Brazilian Society of Urology.

Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder.

C. Dinney, A. Pollack, C. Pettaway, 1998, The Journal of urology.

Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort.

Yair Lotan, Umberto Capitanio, Maximilian Burger, 2010, European urology.

Significance of upper urinary tract urothelial thickening and filling defect seen on MDCT urography in patients with a history of urothelial neoplasms.

H. Grossman, C. Ng, C. Dinney, 2010, AJR. American journal of roentgenology.

Risk group stratification in patients with micropapillary bladder cancer treated with radical cystectomy and/or neoadjuvant chemotherapy.

B. Czerniak, S. Parikh, C. Dinney, 2015 .

Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy

Y. Lotan, G. Sonpavde, C. Dinney, 2010, BJU international.

Ultrasound‐guided transperineal needle biopsy of the prostate after abdominoperineal resection

C. Dinney, Patricia Troncoso, Bruno D. Fornage, 1995, Journal of clinical ultrasound : JCU.

A feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer.

C. Dinney, P. Troncoso, R. Babaian, 1999, The Journal of urology.

Unique somatic variants in DNA from urine exosomes of individuals with bladder cancer

T. Gilliam, M. D'Souza, N. Maltsev, 2021, Molecular therapy. Methods & clinical development.

Regional Effects of an Antivascular Endothelial Growth Factor Receptor Monoclonal Antibody on Receptor Phosphorylation and Apoptosis in Human 253J B-V Bladder Cancer Xenografts

C. Dinney, D. Hicklin, D. McConkey, 2004, Cancer Research.

The Willet F. Whitmore, Jr., Lectureship: blockade of epidermal growth factor receptors as anticancer therapy.

C. Dinney, J. Mendelsohn, John Mendelsohn, 2001, The Journal of urology.

Assessment of Luminal and Basal Phenotypes in Bladder Cancer

J. Weinstein, D. Cogdell, B. Czerniak, 2020, Scientific Reports.

Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways

K. Baggerly, G. Fuller, Wei Zhang, 2005, Laboratory Investigation.

Phase III Prevention Trial of Fenretinide in Patients with Resected Non–Muscle-Invasive Bladder Cancer

A. Sabichi, H. Parnes, S. Lippman, 2008, Clinical Cancer Research.

Phase III PreventionTrial of Fenretinide in Patients with Resected Non ^ Muscle-Invasive Bladder Cancer

A. Sabichi, H. Parnes, S. Lippman, 2007 .

Association of Polymorphisms in Oxidative Stress Genes with Clinical Outcomes for Bladder Cancer Treated with Bacillus Calmette-Guérin

Xifeng Wu, C. Dinney, D. Chang, 2012, PloS one.

Matrix Metalloproteinase Polymorphisms Are Associated with Bladder Cancer Invasiveness

Jian Gu, Jie Lin, Xifeng Wu, 2007, Clinical Cancer Research.

Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness.

J. Gu, Xifeng Wu, H. Grossman, 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.

Treatment Paradigms in Bladder Cancer: Clinical Implications of Histological and Molecular Analysis

C. Dinney, M. Adibi, 2018 .

Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients.

U. Capitanio, Y. Lotan, A. Sagalowsky, 2009, The Journal of urology.

Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases.

B. Czerniak, C. Dinney, A. Kamat, 2018, Human pathology.

Mutations Within the Kinase Domain and Truncations of the Epidermal Growth Factor Receptor Are Rare Events in Bladder Cancer: Implications for Therapy

K. Aldape, O. Bogler, H. Grossman, 2006, Clinical Cancer Research.

Uncommon Cancers of the Bladder

R. Millikan, B. Czerniak, C. Dinney, 2006 .

Office cystoscopy and transrectal ultrasound-guided prostate biopsies pose minimal risk: prospective evaluation of 921 procedures.

C. Dinney, S. Matin, T. Feeley, 2009, Urology.

Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test.

K. Baggerly, Y. Lotan, D. Cogdell, 2018, European urology focus.

A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC 14 A 1 , a urea transporter gene on chromosome 18 q 12 . 3

M. Thun, N. Malats, M. Kogevinas, 2011 .

Fluid intake, genetic variants of UDP-glucuronosyltransferases, and bladder cancer risk

C. Dinney, A. Kamat, H. Barton Grossman, 2013, British Journal of Cancer.

Boosted C5 Trees i-Biomarkers Panel for Invasive Bladder Cancer Progression Prediction

Alexandru George Floares, Irina Luludachi, Colin Dinney, 2011, CIBB.

Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer.

C. Dinney, P. Black, G. Brown, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall survival in older patients with cancer

V. Valero, D. Tripathy, C. Dinney, 2018, BMJ Supportive & Palliative Care.

The efficacy and complications of salvage cryotherapy of the prostate.

C. Dinney, R. Babaian, A. V. von Eschenbach, 1997, The Journal of urology.

Comparison between whole mount tissue preparations and virtual tissue microarray samples for measuring Ki-67 and apoptosis indices in human bladder cancer

B. Czerniak, C. Dinney, J. Bondaruk, 2016, Medicine.

463: Management of Primary Carcinomas of the Male Urethra

C. Dinney, P. Spiess, A. Kamat, 2006 .

Contralateral pleural effusion secondary to nonmetastatic renal cell carcinoma.

C. Dinney, R. Norman, 1990, The Journal of urology.

Plasma vitamins E and A and risk of bladder cancer: a case–control analysis

Xifeng Wu, C. Dinney, Jie Lin, 2008, Cancer Causes and Control.

The role of metastatic burden in cytoreductive/consolidative radical cystectomy

C. Dinney, F. Petros, A. Kamat, 2019, World Journal of Urology.

Risk factors for falls in older patients with cancer

V. Valero, D. Tripathy, C. Dinney, 2017, BMJ Supportive & Palliative Care.

Revisiting an Old Conundrum: A Systematic Review and Meta-Analysis of Intravesical Therapy for Treatment of Urothelial Carcinoma of the Prostate

C. Dinney, A. Kamat, N. Brooks, 2021, Bladder cancer.

Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience

W. Murphy, V. Valero, D. Tripathy, 2018, Supportive Care in Cancer.

Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience.

Wassim Kassouf, C. Dinney, M. Munsell, 2006, The Journal of urology.

Diagnostic testing for prostate cancer detection: less is best.

C. Dinney, R. Babaian, R. Evans, 1993, Urology.

Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer

Y. Lotan, C. Dinney, T. Morgan, 2021, The Journal of urology.

Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.

B. Czerniak, C. Dinney, D. McConkey, 2017, European urology focus.

Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.

C. Dinney, A. Kamat, J. Shah, 2016, European urology.

Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop.

S. Groshen, B. Vikram, C. Dinney, 2014, Urology.

The stabilization and targeting of surfactant-synthesized gold nanorods

Rebekah A Drezek, Kathryn M Mayer, Jason H Hafner, 2009, Nanotechnology.

Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma.

S. Boorjian, C. Dinney, Yu Shen, 2018, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Clinical Cancer esearch cer Therapy : Clinical Effectiveness of Off-Protocol Adjuvant Chemotherapy for R ients with Urothelial Carcinoma of the Urinary Bladder

A. Sagalowsky, C. Dinney, S. Shariat, 2010 .

Bladder cancer: narrowing the gap between evidence and practice.

D. Lamm, C. Dinney, B. Bochner, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multiplexed, particle‐based flow cytometric assay identified plasma matrix metalloproteinase‐7 to be associated with cancer‐related death among patients with bladder cancer

Xifeng Wu, C. Dinney, Jie Lin, 2010, Cancer.

Inhibition of Inducible Heat Shock Protein-70 (Hsp72) Enhances Bortezomib-Induced Cell Death in Human Bladder Cancer Cells

C. Dinney, D. McConkey, A. Siefker-Radtke, 2013, PloS one.

Radical cystectomy for stage T3b bladder cancer.

C. Dinney, C. Hall, 1996, Seminars in urologic oncology.

Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity

C. Dinney, M. Munsell, A. Kamat, 2010, BJU international.

Two synchronous primary tumors of the ovary and kidney: a case report.

C. L. Edwards, C. Dinney, A. Kudelka, 1996, European Journal of Gynaecological Oncology.

A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer

R. Millikan, C. Dinney, Yu Shen, 2013, Cancer.

Review of the M.D. Anderson experience in the treatment of bladder sarcoma.

B. Czerniak, C. Dinney, P. Spiess, 2007, Urologic oncology.

Bacillus Calmette-Guérin Salvage Therapy: Definitions and Context.

C. Dinney, V. Narayan, B. Konety, 2020, The Urologic clinics of North America.

Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.

C. Dinney, W. Benedict, B. Hutchins, 2013, The Journal of urology.

Concomitant Carcinoma in situ in Cystectomy Specimens Is Not Associated with Clinical Outcomes after Surgery

F. Montorsi, G. Sonpavde, C. Dinney, 2011, Urologia Internationalis.

A combination of intravesical and BCG electromotive mitomycin for high-risk superficial bladder cancer

C. Dinney, A. Kamat, 2006, Nature Clinical Practice Urology.

913: Results of a Randomized Chemoprevention Trial with Fenretinide in Non-Muscle Invasive Bladder Cancer

A. Sabichi, S. Lippman, C. Dinney, 2005 .

Clinical significance of ureteric ‘skip lesions’ at the time of radical cystectomy: the M.D. Anderson experience and literature review

C. Wood, C. Dinney, A. Kamat, 2014, BJU international.

Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy.

C. Dinney, A. Kamat, J. Shah, 2014, Urology.

Mitochondrial DNA Content as Risk Factor for Bladder Cancer and Its Association with Mitochondrial DNA Polymorphisms

Xifeng Wu, Y. Ye, C. Dinney, 2015, Cancer Prevention Research.

MP65-02 A PHASE III SURGICAL TRIAL TO EVALUATE THE BENEFIT OF A STANDARD VERSUS AN EXTENDED PELVIC LYMPHADENECTOMY PERFORMED AT TIME OF RADICAL CYSTECTOMY FOR MUSCLE INVASIVE UROTHELIAL CANCER: SWOG S1011 (NCT #01224665)

I. Thompson, C. Tangen, A. Kibel, 2015 .

The risk of upper tract recurrence following cystectomy in patients with transitional cell carcinoma involving the distal ureter.

C. Dinney, S. Tanguay, P. Kenworthy, 1996, The Journal of urology.

Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes.

C. Wood, C. Dinney, John W. Davis, 2017, Journal of endourology.

Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction.

C. Dinney, P. Spiess, A. Kamat, 2008, The Journal of urology.

The current status of gene therapy in bladder cancer

C. Dinney, C. Tholomier, Sharada Mokkapati, 2023, Expert review of anticancer therapy.

A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder.

H. Grossman, C. Dinney, J. Slaton, 1999, The Journal of urology.

Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy: Implications for survivorship.

C. Dinney, A. Sood, A. Kamat, 2022, Urologic oncology.

Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma

Y. Lotan, C. Dinney, T. Morgan, 2020, BJU international.

Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy

C. Dinney, P. Spiess, P. Black, 2016, World Journal of Urology.

Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder.

H. Grossman, C. Dinney, W. Mcdougal, 1998, The Journal of urology.

Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients.

Y. Lotan, A. Sagalowsky, G. Sonpavde, 2010, The Journal of urology.

A phase II trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine (IAG), followed by cisplatin, gemcitabine and ifosfamide (CGI) in locally advanced urothelial cancer (UC): Final results from the M.D. Anderson Cancer Center

R. Millikan, C. Dinney, Yu Shen, 2008 .

Significance of downstaging in muscle-invasive bladder cancer treated with preoperative radiotherapy.

C. Dinney, A. Pollack, G. Zagars, 1997, International journal of radiation oncology, biology, physics.

915: The Case for Early Cystectomy in Non-Muscleinvasive Micropapillary Transitional Cell Carcinoma of the Bladder

R. Millikan, C. Dinney, A. Kamat, 2005 .

Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era

C. Dinney, M. Munsell, A. Kamat, 2006, Cancer.

Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria.

C. Dinney, S. Matin, K. Kennedy, 2010, The Journal of urology.

Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort

Y. Lotan, C. Dinney, T. Morgan, 2023, The Journal of urology.

Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes

C. Dinney, A. Kamat, P. Hensley, 2023, European urology open science.

Reduced‐dose bacillus Calmette‐Guérin (BCG) in an era of BCG shortage: real‐world experience from a tertiary cancer centre

C. Dinney, A. Kamat, P. Hensley, 2021, BJU international.

Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes.

C. Dinney, A. Kamat, Roger Li, 2021, European urology oncology.

Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.

C. Dinney, A. Kamat, Roger Li, 2019, European urology oncology.

Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer.

Jim C Hu, K. Hoffman, C. Dinney, 2017, European urology focus.

Can we reliably identify patients for radical cystectomy without neoadjuvant chemotherapy?

R. Millikan, C. Dinney, A. Kamat, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk of urethral, vaginal and cervical involvement in patients undergoing radical cystectomy for bladder cancer: results of a contemporary cystectomy series from M. D. Anderson Cancer Center.

C. Dinney, M. Chen, A. Malpica, 1997, The Journal of urology.

Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells.

C. Dinney, D. McConkey, A. Papageorgiou, 2007, Cancer biology & therapy.

Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein.

C. Dinney, R. Connor, W. Benedict, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Erratum: A combination of intravesical BCG and electromotive mitomycin for high-risk superficial bladder cancer (Nature Clinical Practice Urology (2006) vol. 3 (472-473) 10.1038/ncpuro0559))

C. Dinney, A. Kamat, 2006 .

Urinary nuclear matrix protein 22 (NMP22): A diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional‐cell carcinoma of the bladder

C. Dinney, H. Fritsche, R. Katz, 1999, Diagnostic cytopathology.

Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the University of Texas M. D. Anderson Cancer Center.

R. Millikan, C. Dinney, S. Matin, 2012 .

Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy

C. Dinney, A. Kamat, P. Hensley, 2021, The Journal of urology.

A phase I study of intravesical Ad-IFN in superficial bladder cancer patients.

C. Dinney, W. Benedict, M. O'Donnell, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC).

P. Sharma, C. Dinney, Jianjun Gao, 2019, Journal of Clinical Oncology.

Reply to Mattias Aine, Fredrik Liedberg, Gottfrid Sjödahl, and Mattias Höglund's Letter to the Editor re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur Urol 2014;66:609-10.

C. Dinney, D. McConkey, W. Choi, 2015, European urology.

The role of chemotherapy in the management of the patient with T3b bladder cancer.

R. Millikan, C. Dinney, 1996, Seminars in urologic oncology.

EVIDENCE-BASED GENDER RELATED OUTCOMES AFTER RADICAL CYSTECTOMY: RESULTS OF A LARGE MULTICENTER STUDY

F. Montorsi, Y. Lotan, A. Sagalowsky, 2009 .

Self-assembled fluorescent magnetic nanoprobes for multimode-biomedical imaging.

Yong-Min Huh, Seungjoo Haam, Eun-Kyung Lim, 2010, Biomaterials.

Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a Phase l study

C. Dinney, W. Benedict, M. Munsell, 2014, Cancer Gene Therapy.

Direct cytotoxicity produced by adenoviral-mediated interferon α gene transfer in interferon-resistant cancer cells involves ER stress and caspase 4 activation

C. Dinney, W. Benedict, Z. Yang, 2011, Cancer Gene Therapy.

Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease

C. Dinney, R. Sylvester, A. Kamat, 2017, Bladder cancer.

Re: Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer.

C. Dinney, V. Narayan, A. Lim, 2019, European Urology.

Organ preservation for muscle-invasive bladder cancer by transurethral resection.

Xifeng Wu, C. Dinney, C. Pettaway, 2007, Urology.

Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial

Anirban P. Mitra, G. Andriole, Y. Lotan, 2021, European Urology.

1521: Variant Histology in Bladder Cancer - Experience in 1246 Patients Undergoing Cystectomy

R. Millikan, C. Dinney, M. Munsell, 2007 .

A phase II randomized four-regimen selection trial incorporating response for sequential chemotherapy in metastatic, unresectable urothelial cancer: Final results from the M. D. Anderson Cancer Center.

R. Millikan, C. Dinney, A. Kamat, 2009, Journal of Clinical Oncology.

Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette–Guerin Instillation for Non-muscle Invasive Bladder Cancer

Xifeng Wu, Y. Ye, C. Dinney, 2015, Annals of Surgical Oncology.

Urine cell-based DNA methylation classifier for monitoring bladder cancer

L. Kiemeney, B. Czerniak, J. Witjes, 2018, Clinical Epigenetics.

Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience

S. Parikh, C. Dinney, A. Kamat, 2014 .

Oncologic equipoise between robotic and open radical cystectomy.

C. Dinney, V. Narayan, Roger Li, 2021, Journal of endourology.

Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults.

C. Dinney, L. Levy, C. Rosser, 2003, Urology.

INTRAOPERATIVE LYMPHATIC MAPPING TO DETECT INGUINAL METASTASES IN PENILE CARCINOMA: RESULTS OF A PILOT STUDY

C. Dinney, R. Babaian, C. Pettaway, 1999 .

A combination of intravesical BCG [corrected] and [corrected] electromotive mitomycin for high-risk superficial bladder cancer.

C. Dinney, A. Kamat, 2006, Nature Clinical Practice Urology.

Re: A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: Final results

R. Millikan, C. Dinney, Yu Shen, 2013 .

LYMPHOVASCULAR INVASION IS A POWERFUL PREDICTOR OF CLINICAL OUTCOMES IN NODE-NEGATIVE RADICAL CYSTECTOMY PATIENTS: AN INTERNATIONAL EXTERNAL VALIDATION STUDY

U. Capitanio, F. Montorsi, Y. Lotan, 2009 .

Bladder cancer.

C. Dinney, 2020, Urologic oncology.

Words of wisdom. Re: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer.

C. Dinney, R. Svatek, 2009, European urology.

Urachal carcinoma: a pathologic and clinical study of 46 cases.

B. Czerniak, C. Dinney, A. Kamat, 2015, Human pathology.

High risk populations and cystectomy outcomes.

C. Dinney, L. Elting, R. Svatek, 2009, The Journal of urology.

MP83-12 IN VITRO EFFECTS OF INTERFERON ALPHA IN BLADDER CANCER: IMMUNE CHECKPOINT EXPRESSION AND MICRORNA AND MRNA GENOMIC PROFILING

C. Dinney, D. McConkey, W. Choi, 2016 .

Non-seminomatous germ cell tumor with bone metastasis only at diagnosis: A rare clinical presentation

C. Dinney, Jianjun Gao, J. Karam, 2016, Asian journal of urology.

A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy

Y. Lotan, C. Dinney, T. Morgan, 2016 .

Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval

C. Dinney, C. Tholomier, Sharada Mokkapati, 2023, Frontiers in immunology.

Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis

J. Hazle, C. Dinney, D. McConkey, 2010, BJU international.

Malnutrition and overall survival in older patients with cancer.

V. Valero, C. Dinney, D. Tripathy, 2020, Clinical nutrition.

miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy

G. Calin, M. Nicoloso, C. Dinney, 2009, Clinical Cancer Research.

The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside

C. Dinney, D. McConkey, J. Duplisea, 2018, World Journal of Urology.

Intelligent Clinical Decision Support Systems for Non-invasive Bladder Cancer Diagnosis

Jing Wang, Alexandru G. Floares, Tiberiu Popa, 2010, CIBB.

Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis.

Y. Lotan, C. Dinney, T. Curiel, 2014, Urology.

Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer.

Y. Lotan, A. Sagalowsky, G. Sonpavde, 2011, The Journal of urology.

Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33.

David M. Thomas, Krista A. Zanetti, Geoffrey S. Tobias, 2014, Human molecular genetics.

Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells

C. Dinney, D. McConkey, B. Davies, 2012, Cancer biology & therapy.

The Molecular, the Bad, and the Ugly: Preventing Bladder Cancer via mTOR Inhibition

C. Dinney, D. McConkey, 2009, Cancer Prevention Research.

In situ activation of mouse lung macrophages by coadministration of liposomes containing the lipopeptide CGP 31362 and interleukin 2 involves interaction with T lymphocytes and natural killer cells.

C. Dinney, I. Fidler, J. Killion, 1991, Lymphokine and cytokine research.

Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center.

R. Millikan, C. Dinney, Yu Shen, 2013, European urology.

Benzo(a)pyrene Diol Epoxide-Induced Chromosome 9p21 Aberrations Are Associated with Increased Risk of Bladder Cancer

Xifeng Wu, C. Dinney, Y. Horikawa, 2008, Cancer Epidemiology Biomarkers & Prevention.

Mitochondrial DNA Content as Risk Factor for Bladder Cancer and Its Association with Mitochondrial DNA Polymorphisms

Xifeng Wu, C. Dinney, D. Chang, 2015, Cancer Prevention Research.

The effect of cisplatin-based neoadjuvant chemotherapy on the renal function of patients undergoing radical cystectomy.

Y. Lotan, C. Dinney, S. Daneshmand, 2023, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Energy Balance, the PI3K-AKT-mTOR Pathway Genes, and the Risk of Bladder Cancer

Xifeng Wu, H. Grossman, C. Dinney, 2010, Cancer Prevention Research.

Management of urethral recurrence after orthotopic urinary diversion

C. Dinney, M. Munsell, A. Kamat, 2009, BJU international.

Re: Nomograms provide improved accuracy for predicting survival after radical cystectomy.

C. Dinney, P. Black, 2007, European urology.

Nucleotide Excision Repair Gene Polymorphisms and Recurrence after Treatment for Superficial Bladder Cancer

J. Gu, Xifeng Wu, C. Dinney, 2005, Clinical Cancer Research.

The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward

C. Dinney, Sharada Mokkapati, Alexis R. Steinmetz, 2024, Bladder Cancer.

The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder

R. Millikan, A. Sagalowsky, C. Dinney, 2010, Clinical Cancer Research.

Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer?

C. Dinney, D. McConkey, M. Bar‐eli, 2008, The Journal of urology.

Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.

C. Dinney, B. Hutchins, A. Kamat, 2013, The Journal of urology.

C. Dinney, D. McConkey, W. Choi, 2015, European urology.